Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594522 · ClinicalTrials.gov registry record · Phase 1
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07594522: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07594522 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07594522, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
Interventions
- DRUG Ivonescimab
- RADIATION Photon or Proton standard stereotactic body radiotherapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2028-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594522
The ClinicalTrials.gov registry entry for NCT07594522 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ivonescimab is the first listed.
NCT07594522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594522 about?
NCT07594522 is a clinical study titled "A Study of Ivonescimab in People With Non-Small Cell Lung Cancer". The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
What is the current status of trial NCT07594522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-05-12. Estimated completion is 2028-05-12.
What interventions are being tested in trial NCT07594522?
The interventions under investigation include: Ivonescimab (DRUG), Photon or Proton standard stereotactic body radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT07594522?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.